Lewy body dementia (LBD) and Alzheimer’s disease both cause progressive cognitive decline, but they differ in which symptoms appear first, how they progress, and how the brain is affected at a cellular level. Alzheimer’s typically starts with memory loss, while LBD often begins with changes in attention, visual perception, and alertness, sometimes accompanied by vivid hallucinations and movement problems. These distinctions matter because the two conditions respond differently to treatment, and some medications that are routine in dementia care can be dangerous for people with LBD.
What Happens in the Brain
Alzheimer’s disease is driven by two abnormal proteins: amyloid-beta, which clumps into plaques between brain cells, and tau, which tangles inside neurons. Together, these deposits gradually destroy the networks responsible for forming and retrieving memories.
Lewy body dementia involves a different protein called alpha-synuclein, which folds incorrectly and accumulates into round clumps known as Lewy bodies inside nerve cells. These deposits disrupt the brain’s dopamine and acetylcholine signaling, which explains why LBD affects movement, attention, and perception so prominently. Interestingly, the pathology isn’t always clean-cut: up to 50% of Alzheimer’s cases also show Lewy bodies at autopsy, creating an overlap that can make diagnosis tricky during life.
How Early Symptoms Differ
Alzheimer’s is often called a “memory-plus” syndrome. The hallmark early sign is progressive difficulty learning and storing new information. A person with Alzheimer’s may ask the same question repeatedly or forget a conversation entirely, and giving them a hint or cue typically doesn’t help them retrieve the lost memory. Over time, a second area of thinking, such as language or planning, also declines.
LBD can also impair memory, but the nature of that impairment is different. People with LBD often have trouble retrieving information on demand yet can recall it when given a prompt or a multiple-choice cue. More distinctive, though, are early problems with attention, executive function, and visual-spatial perception. Someone with LBD might misjudge distances, struggle to assemble objects, or have trouble sustaining focus on a task.
One of the most recognizable features of LBD is fluctuating cognition. This means a person can seem sharp and engaged one hour, then become drowsy, confused, or stare blankly the next. These swings can happen minute to minute or day to day, and they look nothing like the steady, gradual slide that characterizes Alzheimer’s. Family members often describe it as the person “coming and going.”
Visual Hallucinations
Hallucinations are one of the clearest dividing lines between the two diseases. In LBD, vivid visual hallucinations often appear early, sometimes even before significant memory loss. People commonly see fully formed images of people, animals, or objects that aren’t there. These hallucinations frequently move, and the person may also report shadows in their peripheral vision or misperceive real objects as something else (seeing a coat rack as a person, for example). About one-third of LBD patients hallucinate people, and roughly 16% see animals.
Alzheimer’s can produce hallucinations too, but they’re far less common and usually emerge later in the disease. Only about 4% of Alzheimer’s patients experience visual hallucinations of people, and peripheral “shadow” hallucinations occur in under 2%, compared to nearly 18% in LBD. When psychosis does appear in Alzheimer’s, delusions (false beliefs, like thinking someone is stealing from them) are more typical than seeing things.
Movement Problems and Sleep
Many people with LBD develop Parkinsonism: stiffness, slow movement, a shuffling walk, or reduced facial expression. These motor symptoms can appear around the same time as cognitive changes or within the first year. If someone has had Parkinson’s disease for more than a year before cognitive symptoms emerge, the diagnosis shifts to Parkinson’s disease dementia rather than LBD. This “one-year rule” is the clinical convention for distinguishing the two, though the underlying brain pathology is similar.
Alzheimer’s does not typically cause Parkinsonism until very late stages, if at all.
REM sleep behavior disorder (RBD) is another strong signal pointing toward LBD rather than Alzheimer’s. People with RBD physically act out their dreams during sleep, sometimes thrashing, kicking, or yelling. RBD is now recognized as a core diagnostic feature of LBD and is one of the strongest early predictors of synuclein-related brain diseases. It can precede cognitive symptoms by years or even decades. In longitudinal studies, only about 3% to 11% of people with RBD eventually develop Alzheimer’s; the vast majority develop LBD or Parkinson’s disease instead.
How Each Is Diagnosed
Alzheimer’s is typically diagnosed through a combination of cognitive testing, medical history, and increasingly, biomarker tests that detect amyloid and tau (through spinal fluid analysis or specialized PET scans).
LBD diagnosis relies more heavily on the clinical picture. The current consensus criteria require dementia plus at least two of four core features: fluctuating cognition, recurrent visual hallucinations, Parkinsonism, or REM sleep behavior disorder. When the clinical picture is ambiguous, a brain imaging test called a DaTscan can help. This scan measures dopamine transporter activity in the basal ganglia. In healthy brains and in Alzheimer’s, the scan lights up in a comma-shaped pattern on both sides. In LBD, uptake is reduced, reflecting the loss of dopamine-producing neurons. Reduced dopamine transporter uptake on this scan is considered one of the strongest biomarkers for distinguishing LBD from Alzheimer’s.
Another supportive clue is reduced blood flow to the back of the brain (the occipital region) on perfusion imaging, a pattern more common in LBD than Alzheimer’s and consistent with the visual processing problems these patients experience.
A Critical Medication Difference
This is perhaps the most important practical distinction between the two conditions. People with LBD can have severe, even fatal, reactions to certain antipsychotic medications. Traditional antipsychotics like haloperidol should generally never be prescribed to someone with LBD. Even newer antipsychotics like olanzapine and risperidone carry elevated risks, including dramatically worsened stiffness and movement problems, extreme sedation, dangerous drops in blood pressure, and in rare cases, a life-threatening reaction called neuroleptic malignant syndrome.
These same medications are sometimes used in Alzheimer’s patients to manage agitation or psychosis (though they carry risks for all elderly people with dementia). The heightened sensitivity in LBD means that an accurate diagnosis isn’t just an academic exercise. Getting the wrong label can lead to a prescription that makes things significantly worse.
Progression and Survival
Both diseases are progressive and currently have no cure, but LBD tends to move faster. A retrospective study comparing the two found that median survival from diagnosis was approximately 3.7 years for LBD, compared to nearly 7 years for Alzheimer’s. After adjusting for age, other health conditions, and antipsychotic use, the gap remained substantial: about 3.3 to 4.0 years for LBD (depending on sex) versus 6.7 to 7.0 years for Alzheimer’s.
The faster decline in LBD may partly reflect its broader impact on the body. While Alzheimer’s primarily affects cognition, LBD disrupts the autonomic nervous system (causing blood pressure drops, constipation, and dizziness), impairs sleep, and compromises movement, all of which compound the burden on overall health.
Prevalence
Alzheimer’s disease is far more common. It accounts for 60% to 70% of all dementia cases worldwide, with an estimated 32 million people living with biomarker-confirmed Alzheimer’s dementia globally as of 2023. LBD is the second most common form of degenerative dementia, typically estimated at 5% to 10% of all dementia cases. Because its symptoms overlap with both Alzheimer’s and Parkinson’s disease, LBD is widely considered underdiagnosed, and many people likely carry an incorrect label for years before the full clinical picture becomes clear.